Virtu Financial LLC acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 18,320 shares of the biopharmaceutical company's stock, valued at approximately $467,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of RPRX. Brooklyn Investment Group lifted its stake in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 876 shares during the last quarter. Allworth Financial LP lifted its position in shares of Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares during the last quarter. Riverview Trust Co boosted its holdings in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp boosted its holdings in shares of Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. grew its position in shares of Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 1,003 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.
Wall Street Analyst Weigh In
RPRX has been the subject of a number of research reports. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday. TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $41.60.
Read Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Trading Down 0.9 %
NASDAQ:RPRX traded down $0.28 during mid-day trading on Friday, reaching $31.37. The company's stock had a trading volume of 4,077,104 shares, compared to its average volume of 3,103,202. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company's fifty day simple moving average is $32.44 and its two-hundred day simple moving average is $28.85. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market cap of $18.08 billion, a P/E ratio of 21.63, a P/E/G ratio of 2.31 and a beta of 0.47.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were given a $0.22 dividend. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma's dividend payout ratio is presently 60.69%.
Royalty Pharma Company Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Recommended Stories
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
